StimAire has invented a revolutionary sleep apnea treatment that utilizes a neuromodulation platform that can be injected through a needle in a doctor’s office in under 15 minutes. Our injectable is one of the smallest and least invasive neuromodulation devices in the market.

Our first clinical target is obstructive sleep apnea which is a $30 billion market worldwide. Our device eliminates major surgery and a hospital stay, creating a patient-friendly solution for healthy sleep. Current solutions require at least one night’s stay at a hospital because the surgery is substantially more invasive.

In a recent human clinical trial study, they saw positive results in injecting the hypoglossal nerve stimulator for treating Obstructive Sleep Apnea. There were no adverse events, and efficacy results were as expected.

StimAire has a rich intellectual property portfolio that only begins with this first application. Our platform has the potential to treat bladder urgency, gastrointestinal diseases, autoimmune disorders, depression, pain, cluster headaches, and more.